Nature Communications (Feb 2021)
Dual functions of SPOP and ERG dictate androgen therapy responses in prostate cancer
- Tiziano Bernasocchi,
- Geniver El Tekle,
- Marco Bolis,
- Azzurra Mutti,
- Arianna Vallerga,
- Laura P. Brandt,
- Filippo Spriano,
- Tanya Svinkina,
- Marita Zoma,
- Valentina Ceserani,
- Anna Rinaldi,
- Hana Janouskova,
- Daniela Bossi,
- Manuela Cavalli,
- Simone Mosole,
- Roger Geiger,
- Ze Dong,
- Cai-Guang Yang,
- Domenico Albino,
- Andrea Rinaldi,
- Peter Schraml,
- Simon Linder,
- Giuseppina M. Carbone,
- Andrea Alimonti,
- Francesco Bertoni,
- Holger Moch,
- Steven A. Carr,
- Wilbert Zwart,
- Marianna Kruithof-de Julio,
- Mark A. Rubin,
- Namrata D. Udeshi,
- Jean-Philippe P. Theurillat
Affiliations
- Tiziano Bernasocchi
- Institute of Oncology Research, Faculty of Biomedical Sciences, Università della Svizzera italiana
- Geniver El Tekle
- Institute of Oncology Research, Faculty of Biomedical Sciences, Università della Svizzera italiana
- Marco Bolis
- Institute of Oncology Research, Faculty of Biomedical Sciences, Università della Svizzera italiana
- Azzurra Mutti
- Institute of Oncology Research, Faculty of Biomedical Sciences, Università della Svizzera italiana
- Arianna Vallerga
- Institute of Oncology Research, Faculty of Biomedical Sciences, Università della Svizzera italiana
- Laura P. Brandt
- Department of Biomedical Research, University of Bern
- Filippo Spriano
- Institute of Oncology Research, Faculty of Biomedical Sciences, Università della Svizzera italiana
- Tanya Svinkina
- The Broad Institute of MIT & Harvard
- Marita Zoma
- Institute of Oncology Research, Faculty of Biomedical Sciences, Università della Svizzera italiana
- Valentina Ceserani
- Institute of Oncology Research, Faculty of Biomedical Sciences, Università della Svizzera italiana
- Anna Rinaldi
- Institute of Oncology Research, Faculty of Biomedical Sciences, Università della Svizzera italiana
- Hana Janouskova
- Institute of Oncology Research, Faculty of Biomedical Sciences, Università della Svizzera italiana
- Daniela Bossi
- Institute of Oncology Research, Faculty of Biomedical Sciences, Università della Svizzera italiana
- Manuela Cavalli
- Institute of Oncology Research, Faculty of Biomedical Sciences, Università della Svizzera italiana
- Simone Mosole
- Institute of Oncology Research, Faculty of Biomedical Sciences, Università della Svizzera italiana
- Roger Geiger
- Institute for Research in Biomedicine
- Ze Dong
- State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences
- Cai-Guang Yang
- State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences
- Domenico Albino
- Institute of Oncology Research, Faculty of Biomedical Sciences, Università della Svizzera italiana
- Andrea Rinaldi
- Institute of Oncology Research, Faculty of Biomedical Sciences, Università della Svizzera italiana
- Peter Schraml
- Department of Pathology and Molecular Pathology, University Hospital Zurich
- Simon Linder
- The Netherlands Cancer Institute, Oncode Institute
- Giuseppina M. Carbone
- Institute of Oncology Research, Faculty of Biomedical Sciences, Università della Svizzera italiana
- Andrea Alimonti
- Institute of Oncology Research, Faculty of Biomedical Sciences, Università della Svizzera italiana
- Francesco Bertoni
- Institute of Oncology Research, Faculty of Biomedical Sciences, Università della Svizzera italiana
- Holger Moch
- Department of Pathology and Molecular Pathology, University Hospital Zurich
- Steven A. Carr
- The Broad Institute of MIT & Harvard
- Wilbert Zwart
- The Netherlands Cancer Institute, Oncode Institute
- Marianna Kruithof-de Julio
- Department of Biomedical Research, Urology Research Laboratory, University of Bern
- Mark A. Rubin
- Department of Biomedical Research, University of Bern
- Namrata D. Udeshi
- The Broad Institute of MIT & Harvard
- Jean-Philippe P. Theurillat
- Institute of Oncology Research, Faculty of Biomedical Sciences, Università della Svizzera italiana
- DOI
- https://doi.org/10.1038/s41467-020-20820-x
- Journal volume & issue
-
Vol. 12,
no. 1
pp. 1 – 18
Abstract
Gene fusions involving the ERG transcription factor and point mutations in the ubiquitin ligase adaptor SPOP are two truncal mutations that are mutually exclusively present in prostate cancer. Here, the authors show that mutations in SPOP render prostate tumor cells sensitive to antiandrogen therapy and that the presence of ERG promotes sensitivity to high dose of androgen and SPOP inhibition.
